Harvoni is one of Gilead Sciences’ (GILD) largest-selling drugs. A combination of Ledipasvir and Sofosbuvir, it is approved for the treatment of hepatitis C infections.
The above chart shows Harvoni revenue over the last few quarters. During 3Q17, Harvoni contributed ~15% of Gilead’s revenue, and in 2Q17, it contributed ~21%. Harvoni is approved for use with or without Ribavirin for the treatment of chronic hepatitis C infections of genotypes 1, 4, 5, and 6.
Harvoni revenue fell to $973 million in 3Q17, a 48% fall from the $1.9 billion witnessed in 3Q16. Harvoni sales fell due to patent expiry and competition from other hepatitis C drugs available.
For Harvoni, between 3Q16 and 3Q17, US revenue fell to $718 million from $1.1 billion, European revenue fell to $110 million from $380 million, and international revenue fell to $145 million from $396 million.
Epclusa and Vosevi are Gilead’s new drugs for the treatment of patients with chronic hepatitis C infections of genotypes 1 to 6, with or without cirrhosis. In 3Q17, Epclusa saw revenue of $882 million, driven by strong European and international sales and partially offset by lower US sales. Vosevi witnessed revenue of $123 million, driven by US sales of $117 million and European sales of $5 million.
Other hepatitis C drugs include Bristol-Myers Squibb’s (BMY) Daklinza and Johnson & Johnson’s (JNJ) Olysio. The iShares US Healthcare ETF (IHE) has a 3.0% exposure to Gilead Sciences (GILD), a 4.6% exposure to Merck (MRK), a 3.1% exposure to Bristol-Myers Squibb (BMY), and an 11.4% exposure to Johnson & Johnson (JNJ).